BRD2 and ovarian hyperstimulation syndrome: A recent Cochrane review has confirmed that tailoring the FSH starting dose on ovarian reserve markers may reduce cases of OHSS, but it has not been able to demonstrate that it improves live birth rates compared to a policy of giving all women 150 IU (41).